Curcumin and its Derivatives Potently Inhibits the T3151 Mutant and Overcomes Mutation-Based Resistance in Chronic Myeloid Leukemia

摘要：

　　Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML),but resistance attributable to kinase domain mutations can lead to relapse.Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to imatinib.The T3151 mutation is clinically significant since CML cells harboring this mutation are insensitive to imatinib and other Bcr-Abl-targeted drugs.

作者: Lixian Wu Yuanzhong Chen Jianhua Xu Yang Liu Kunzhong Zhang Ying Wu Liguang Lou Ruijia Chen Lisen Huang Zhiqiang Zhang Yingjuan Fan

作者单位: Dept.of Pharmacology;Institute of Materia Medica;Fuijan Key Laboratory of Natural Medicine Pharmacol Fujian Institute of Hematology,Union Hospital,FMU,Fuzhou,China Institute of Materia Medica;Dept.of Pharmacochemistry Dept.of Pharmacology Institute of Materia Medica;Dept.of Pharmacochemistry;Fuijan Key Laboratory of Natural Medicine Phar Shanghai Institute of Materia Medica,China Dept.of Pharmacology;Dept.of Pharmacochemistry Institute of Materia Medica

会议类型: 国内会议

会议名称: 2012医学科学前沿暨第二届个体化治疗与抗肿瘤药物研究新趋向研讨会

会议地点: 深圳

会议语种:英文

页码: 404-404

在线出版日期: 2012-07-13（万方平台首次上网日期，不代表论文的发表时间）